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Abstract
Aberrant methylation in gene promoter regions leads to
transcriptional inactivation of cancer-related genes and
plays an integral role in tumorigenesis. This alteration
has been investigated in lung tumors primarily from
smokers, whereas only a few studies involved never-
smokers. Here, we applied methylation-specific polymer-
ase chain reaction to compare the frequencies of the
methylated promoter of p16 and O6-methylguanine-DNA
methyltransferase (MGMT ) genes in lung tumors from
122 patients with non–small cell lung cancer, including
81 smokers and 41 never-smokers. Overall, promoter
methylation was detected in 52.5% (64 of 122) and 30.3%
(37 of 122) of the p16 and MGMT genes, respectively.
Furthermore, the frequency of promoter methylation was
significantly higher among smokers, compared with
never-smokers, for both the p16 [odds ratio (OR) = 3.28;
95% confidence interval (CI) = 1.28–8.39; P = .013] and
MGMT (OR = 3.93; 95% CI = 1.27–12.21; P = .018) genes.
The trend for a higher promotermethylation frequency of
these genes was also observed among female smokers
compared with female never-smokers. Our results sug-
gest an association between tobacco smoking and an
increased incidence of aberrant promoter methylation of
the p16 andMGMT genes in non–small cell lung cancer.
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Introduction
Lung cancer is a very common cause of cancer deaths in
the United States and in western European countries [1,2].
This disease is associated primarily with tobacco smoking
because about 85% of lung cancer patients are smokers,
whereas the remaining 10% to 15% have no history of to-
bacco smoking and consist of mostly women [1]. Other
causes of lung cancer include exposure to coal-burning
smoke [3] and environmental tobacco smoke [4]. In spite of
extensive studies, pathogenic pathways to lung cancer in
both smokers and never-smokers remain poorly understood.
Aberrant methylation of 5V cytosine residues of a guanine
residue in CpG islands in the promoter regions of tumor-
suppressor genes is an importantmechanism of gene transcrip-
tional inactivation and has been associated with tumorigenesis
[5–7]. The p16INK4A tumor-suppressor gene plays a key role in
cell cycle regulation. This gene codes for a protein that binds to
and inhibits cyclin D kinases (CdK4 and CdK6), which normally
phosphorylate serine and threonine residues of the retinoblas-
toma (Rb) protein [8,9]. Therefore, the p16 protein inhibits cell
cycle progression through G1 to S phase by maintaining the Rb
protein in the unphosphorylated state. Inactivation of the p16
gene expression by aberrant methylation of its promoter region
is believed to be a pathway to tumorigenesis [10,11]. Previous
studies show that methylation of the p16 gene promoter was
detected in a high proportion of primary lung tumors [12,13].
Aberrant methylation in the promoter region of the O6-
methylguanine-DNA methyltransferase (MGMT) gene has also
been found frequently in many tumor types, including lung
tumors, and is implicated as a mechanism of gene silencing
leading to tumorigenesis [14,15]. Unlike the p16 protein, how-
ever, the MGMT protein is a DNA repair enzyme, which specif-
ically transfers the methyl group and other small alkyl groups at
the O6 position of guanine to a cysteine acceptor site of the
protein itself in an autoinactivating reaction [16]. Therefore, the
repair activity of the MGMT protein helps decrease the prob-
ability that the damaged guanine becomes a mutagenic/car-
cinogenic site. Methylated MGMT gene promoter has been
associated with loss or decrease ofMGMT expression in tumor
tissues of various organs, including lung tumors [14,17–19].
Taken together, both p16 and MGMT genes have been
considered as potentially useful candidate biomarkers for lung
cancer treatment and early detection. The purpose of this study
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was to understand the prevalence of aberrant promoter
methylation for these two genes in lung tumors from smokers
and never-smokers. We have analyzed methylation in the
promoter region of the p16 and MGMT genes in lung tumors
obtained from lung cancer patients from the Western Penn-
sylvania region. We compared the frequencies of methylated
promoters for these two genes according to smoking status
and gender, and we discussed our results in relation to those
of previous studies.
Materials and Methods
Patients and DNA Isolation
Lung tumor tissues analyzed in this study were obtained
from 122 patients with non–small cell lung cancer, including
81 smokers and 41 never-smokers, all of whom were whites
and lived in the Western Pennsylvania region. They were
among the specimens collected between 1988 and 2001 and
stored at the University of Pittsburgh Medical Center under
an Institutional Review Board–approved protocol. The de-
mographic and clinical profile of these patients is shown in
Table 1. All male smokers were current smokers, and pack-
year data were available for 36 of them. Among female
smokers, 38were current smokersand1wasa former smoker.
Pack-year data were available for 36 of female smokers. One
pack-year is defined as an average of one pack of cigarettes
smoked per day for 1 year. No significant difference in the
number of pack-years was found among male and female
smokers. All never-smokers involved in this study had never
smoked during their lifetime.
Fresh-frozen tissues were used for DNA extraction using
the Proteinase K treatment and phenol/chloroform extraction
methods, as described previously [20]. DNAwas dissolved in
distilled water and stored at 20jC until use.
Methylation-Specific Polymerase Chain Reaction (MSP)
Each genomic DNA sample was treated with sodium bi-
sulfite (Sigma, St. Louis, MO), as described by Herman et al.
[21]. Briefly, DNA was denatured by treatment with 0.3 M
NaOH and incubation at 37jC for 30 minutes, followed by in-
cubation with 10 mM hydroquinone (Sigma) and 3 M sodium
bisulfite (Sigma) at 55jC for 16 to 20 hours. ModifiedDNAwas
purified using a Wizard DNA Clean-Up System (Promega
Corporation,Madison,WI), recovered by ethanol precipitation,
and dissolved in distilled water. Universal methylated human
DNA (Chemicon International, Temecula, CA) was treated in
the same way and was used as a positive control DNA.
Promoter genemethylationwas screened usingMSP. Two
versions of MSP have been previously reported, including an
original one-stage MSP [21] and a modified two-stage MSP,
which used two rounds of PCR and had a higher level of sen-
sitivity to detect promoter methylation compared with the
original one-stage MSP [22]. In this study, we first compared
the sensitivity and validity of both MSP methods to analyze
the promoter methylation of the p16 and MGMT genes in
DNA from a series of 24 lung tumors. The results showed that
promoter methylation was detected in the same tumors and
at a similar frequency using either the original or modified
MSP for both the p16 andMGMT genes, suggesting that the
original one-stage MSP was sufficiently sensitive to detect
promoter methylation in lung tumors. However, in our experi-
ments, the two-stage MSPmethod showedMSP products as
a clear single band through gel electrophoresis analysis,
whereas the one-stage MSP method provided products that
usually appeared with other minor bands (data not shown).
For this reason, in this study, we applied the two-stage MSP
method for promoter methylation analysis. The nucleotide
sequences of the primers used for the two-stage MSP for
both the p16 and MGMT genes are summarized in Table 2.
During round 1 PCR, the primers recognized the bisulfite-
modified template but did not discriminate between the methyl-
ated and unmethylated alleles. PCR amplification was carried
out in a 25-ml reaction mixture containing 10 mM Tris–HCl (pH
8.3), 50 mM KCl, 2 mM MgCl2, 100 mM of each kind of dNTP,
and 0.2 mM of each kind of primer. The reaction was heated at
95jC for 10minutes, then amplified for 40 cycles [95jC/30 sec-
onds, 64jC (for p16) or 52jC (for MGMT)/30 seconds, and
72jC/30 seconds], followed by a final 10-minute extension at
72jC. An aliquot of each round 1 PCR product was diluted 10-
fold, and 1 ml was used for round 2 PCR, using the same
reagents and conditions as for round 1 PCR, except that the
MgCl2 concentration was reduced to 1 mM and each sample
was amplified in two reactions, with one reaction containing
primers specific for methylated C and the other reaction con-
taining primers specific for unmethylated C. Each reaction was
heated at 95jC for 10 minutes, then amplified for 40 cycles,
each consisting (for the reaction containingmethylated primers)
of 95jC/30 seconds, 70jC (for p16) or 64jC (for MGMT)/
30 seconds, and 72jC/30 seconds, and (for the reaction con-
taining unmethylated primers) of 95jC/30 seconds, 64jC (for
both p16 and MGMT)/30 seconds, and 72jC/30 seconds. An
aliquot of each round 2 PCR product was separated on an 8%
polyacrylamide gel. The gel was stained with ethidium bromide
Table 1. Demographic and Clinical Profile of 122 Lung Cancer Patients.
Never-Smokers Smokers
Female (%) Male (%) Female (%) Male (%)
Total 31 10 39 42
Age (years) 66.7 ± 11.0 69.2 ± 6.9 63.1 ± 11.0 64.9 ± 9.1
Smoking (pack-years) NA NA 51.3 ± 20.6 59.6 ± 36.3
Tumor types
Adenocarcinoma 19 (61.3) 4 (40) 22 (56.4) 27 (64.2)
Squamous cell
carcinomas
3 (9.7) 3 (30) 10 (25.6) 6 (14.3)
Bronchoalveolar
carcinoma
6 (19.3) 5 (12.8) 4 (9.5)
Adenosquamous
carcinoma
3 (9.7) 1 (10) 5 (11.9)
Large cell
carcinomas
2 (5.1)
Carcinoid 1 (10)
Neuroendocrine 1 (10)
Tumor stage
I 11 (35.5) 4 (40) 22 (56.4) 17 (40.5)
II 11 (35.5) 1 (10) 8 (20.5) 4 (9.5)
III 3 (9.7) 2 (20) 6 (15.4) 8 (19.0)
IV 5 (16.1) 1 (10) 5 (11.9)
Unknown 1 (3.2) 2 (20) 3 (7.7) 8 (19.0)
NA, not applicable.
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and photographed under UV illumination. The reproducibility of
the results was confirmed by repeating MSP analyses for each
DNA sample.
Round 2 PCR products were also analyzed by restriction
fragment length polymorphism to confirm their ‘‘methylated’’
status. In this method, the round 2 PCR products were
treated with a specific restriction enzyme that cut only
templates containing methylated cytosines (methylated tem-
plate), whereas in unmethylated templates, unmethylated
cytosines were transformed by bisulfite treatment into ura-
cils, which were converted to thymidine after PCR and were
unrecognized by the enzyme. For this purpose, a 2-ml aliquot
from each round 2 PCR product was treated in a final 10-ml
reaction—with the restriction enzyme Fnu4H1 for the p16
gene, and with TaqI and BstU1 for the MGMT gene—using
the reagents and conditions provided by the manufacturer
(New England Biolabs, Beverly, MA) [22]. Digestion products
were separated on an 8% polyacrylamide gel. The gel was
stained with ethidium bromide and photographed under UV
visualization (data not shown).
Statistical Analysis
Wilcoxon rank sum test and chi-square test (or Fisher’s
exact test) were used for continuous and categorical vari-
ables in univariate analysis, respectively. Logistic regression
models were used to assess the effect of multiple variables
on methylation status.
Results
Table 1 shows demographic and clinical information for the
122 lung cancer patients, including 81 smokers and 41
never-smokers. Age did not differ significantly between
smokers and never-smokers, or between male and female
smokers. Adenocarcinomas accounted for 60.5% (49 of 81)
of tumors from smokers and for 56.1% (23 of 41) of those
from never-smokers.
Figure 1 shows a representative example of MSP analysis
of lung tumor DNA. Figure 2 summarizes the results on the
frequency of promoter methylation for the p16 and MGMT
genes. Overall, 52.5% (64 of 122) and 30.3% (37 of 122) of all
patients had a methylated promoter for the p16 and MGMT
genes, respectively. When grouped according to smoking
status, methylated p16 gene promoter was found in 62.9%
(51 of 81) of lung tumors from smokers, which is significantly
higher than the 31.7% (13 of 41) frequency found in those from
never-smokers (P= .001).Whengroupedaccording togender,
a significantly higher frequency of methylated p16 gene pro-
moter was also observed among female smokers compared
with female never-smokers [61.5% (24 of 39) vs 25.8% (8 of
31), P = .002], but not among male smokers compared with
their never-smoking counterparts [64.3% (27 of 42) vs 50% (5
of 10), P = .385], which was probably due to the smaller num-
ber of male never-smokers. There was no statistically signifi-
cant difference in the frequencies of methylated p16 gene
promoter in lung tumors by gender [64.3% (27 of 42) in male
smokers vs 61.5% (24 of 39) in female smokers,P = .808] and
by histology [55.6% (40 of 72) in adenocarcinomas vs 54.5%
(12 of 22) in squamous cell carcinomas, P = .922].
Methylated MGMT gene promoter was found in 39.5%
(32 of 81) of lung tumors from smokers—significantly higher
than the 12.2% (5 of 41) frequency found in those from never-
smokers (P = .002). This trend was also observed among
female smokers versus female never-smokers [28.2% (11 of
39) vs 12.9% (4 of 31), P = .127], and male smokers versus
male never-smokers [50.0% (21 of 42) vs 10.0% (1 of 10),
P = .023]. Among smokers, the methylated MGMT gene pro-
moter occurred more frequently in male [50.0% (21 of 42)]
than in female [28.2% (11 of 39)] patients (P = .045). The fre-
quencies of MGMT gene promoter methylation did not differ
between adenocarcinomas (30.6%, 22 of 72) and squamous
cell carcinomas (27.3%, 6 of 22) (P = .749).
Multivariate logistic regression models were employed to
control for potential confounding effects of variables, such as
age, gender, histology, and tumor stage. As shown in Table 3,
Table 2. Primers Used for MS-PCR.
Sense Primers (5V!3V) Antisense Primers (5V!3V)
Primers for stage I PCR
p16 GAAGAAAGAGGAGGGGTTGG CCACCTAAATCGACCTCCGACCG
MGMT GGATATGTTGGGATAGTT CCAAAAACCCCAAACCC
Primers for stage II PCR
M-p16 TTATTAGAGGGTGGGGCGGATCGC GACCCCGAACCGCGACCGTAA
U-p16 TTATTAGAGGGTGGGGTGGATTGT CAACCCCAAACCACAACCATAA
M-MGMT TTTCGACGTTCGTAGGTTTTCGC GCACTCTTCCGAAAACGAAACG
U-MGMT TTTGTGTTTTGATGTTTGTAGGTTTTTGT AACTCCACACTCTTCCAAAAACAAAACA
M, methylated; U, unmethylated.
Figure 1. Detection of p16 and MGMT promoter methylation by MSP. M in-
dicates the presence of methylated p16 or MGMT. U indicates the presence
of unmethylated p16 or MGMT. All tests were performed twice, and rep-
resentative data are shown.
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smokers had a significantly increased risk for promoter meth-
ylation, compared with never-smokers, for both the p16 [odds
ratio (OR) = 3.28; 95% confidence interval (CI) = 1.28–8.39;
P = .013] andMGMT (OR = 3.93; 95% CI = 1.27–12.21; P =
.018) genes.
Discussion
In the present study, we compared the frequencies of aberrant
promoter methylation for the p16 and MGMT genes with the
smoking status and gender of the patients. Our results show
that the frequency of promoter methylation was significantly
higher among smokers, compared with never-smokers, for
both the p16 [62.9% (51 of 81) vs 31.7% (13 of 41), P = .001]
and MGMT [39.5% (32 of 81) vs 12.2% (5 of 41), P = .002]
genes (Figure 2). Furthermore, the trend for a higher fre-
quency of promoter methylation was also observed among
the group of female smokers compared with the group of
female never-smokers. The difference in the frequencies of
promoter methylation was not associated with the presence
of a different proportion of lung tumor types between the two
patient groups analyzed. For instance, in this study, adeno-
carcinoma accounted for 60.5% (49 of 81) among smokers
and for 56.1% (23 of 41) among never-smokers (Table 1),
whereas the frequency of promoter methylation in this tumor
type was higher among smokers, compared with never-
smokers, for both the p16 [63.3% (31 of 49) vs 39.1% (9 of
23),P = .054] andMGMT [36.7% (18 of 49) vs 17.4% (4 of 23),
P = .094] genes. Logistic regression analysis showed that
tobacco smoking was significantly related to promoter meth-
ylation of both the p16 (OR = 3.28; 95% CI = 1.28–8.39; P =
.013) andMGMT (OR = 3.93; 95%CI = 1.27–12.21;P = .018)
genes. Taken together, these results suggest that aberrant
methylation of the promoter region of the p16 and MGMT
genes may be influenced by tobacco smoking status.
So far, there have been only a few studies involving both
smoking and never-smoking lung cancer patients, and the
results showed some disagreements among studies. For in-
stance, a study [23] of lung cancer patients from multiple
centers, including the United States, Australia, Japan, and Tai-
wan, showed a significantly higher rate ofmethylatedp16gene
promoter in ever-smokers compared with never-smokers (P =
.007). Kim et al. observed the same trend in their study of
172 smoking and 13 nonsmoking lung cancer patients from
the Massachusetts General Hospital (Boston, MA) (P = .05).
Furthermore, the authors showed that the rate of methylated
p16 gene promoter was significantly associated with pack-
years smoked (P = .007) [24]. However, Sanchez-Cespedes
et al. reported a frequency of methylated p16 gene promoter
that was not significantly different between smoking (21.2%,
7 of 33) and nonsmoking (36%, 5 of 14) lung cancer patients
from the Johns Hopkins Hospital (Baltimore, MD), the Johns
Hopkins Bayview Medical Center (Baltimore, MD), and the
Medical College of Wisconsin (Milwaukee, WI) (P = .33) [25].
There have been even fewer studies of the MGMT gene
aberrant promoter methylation in lung tumors from never-
smokers. Pulling et al. analyzed the MGMT gene promoter
methylation in DNA extracted from paraffin-embedded lung
adenocarcinoma obtained from 157 smokers and 46 never-
smokers—consisting mostly of non-Hispanic whites (about
80%) and also of Hispanics and African Americans—from
various centers, including the New Mexico Tumor Registry
(Albuquerque, NM), the SaintMary’sHospital TumorRegistry
(Grand Junction, CO), and the Metropolitan Detroit Cancer
Surveillance System (Detroit, MI). The authors reported a
significantly increased incidence of methylated promoter for
the MGMT gene among never-smokers compared with
smokers (66% vs 47%, respectively, P = .02) [19]. This result
Figure 2. Summary of p16 and MGMT gene hypermethylation in smoking
and never-smoking patients. (**P < .01; *P < .05). Chi-square test or Fisher’s
exact test was used. F, female; M, male.
Table 3. Logistic Regression Models of p16 and MGMT Promoter
Methylation (n = 122).
p16 MGMT
OR (95% CI) P OR (95% CI) P
Age 1.02 (0.97–1.06) .502 1.02 (0.97–1.07) .455
Sex 0.69 (0.29–1.66) .404 0.61 (0.25–1.52) .287
Smoking 3.28 (1.28–8.39) .013 3.93 (1.27–12.2) .018
Histology 0.66 (0.45–0.96) .032 0.98 (0.66–1.46) .927
Stage 0.76 (0.50–1.16) .206 1.26 (0.82–1.95) .291
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is, however, in disagreement with reports by Toyooka et al.
[23] that the frequency of promoter methylation for theMGMT
gene was higher than—but not significantly different from—
that observed in nonsmokers. Our data on the frequencies
of MGMT promoter gene methylation are consistent with
those of Toyooka et al. but are in disagreement with those
of Pulling et al.
The reason for the disagreement on the frequencies
of aberrant promoter methylation for the p16 and MGMT
genes between smokers and never-smokers among different
studies remains unclear. One possible contributing factor to
these inconsistencies may be the smaller number of never-
smokers involved in these studies, due to the smaller inci-
dence of lung cancer occurrence among never-smokers
compared with smokers. Furthermore, a never-smoker or a
nonsmoker has been defined in some studies as a patient
who has smoked less than 100 cigarettes [19,23,25,26],
whereas in our study, it refers to a patient who smoked no
cigarettes during his lifetime. Geographical and/or ethnic dif-
ferences of lung cancer patients among various studies may
also be a factor in the disagreement. For instance, in the
study by Toyooka et al. [23], the majority of nonsmokers were
from Japan and Taiwan, whereas only 20 of them were from
the United States and Australia. Furthermore, it remains un-
clear whether the use of DNA from paraffin-embedded
tumors, such as those used in the study of Pulling et al. [19],
as opposed to DNA from fresh-frozen tumors may affect the
results on the frequencies of gene promoter methylation.
Our data suggest that tobacco smoking correlated with an
increased frequency of promoter methylation for the p16 and
MGMT genes in lung tumors. The reason for this observation
is unknown. Some previous studies showed that tobacco
smoking was associated with alterations of only some genes
in lung cancer. For instance, in lung adenocarcinomas, K-ras
mutations are identified primarily in smokers [27], whereas
mutations in the epidermal growth factor receptor (EGFR)
gene are associated with mostly nonsmokers [28,29]. Lung
cancer patients whose lung tumors had EGFR mutations re-
sponded better than those without such mutations to gefitinib
therapy [30]. The precise mechanism(s) of the association
between tobacco smoking and increased frequencies of p16
and MGMT gene promoter methylation remains to be deter-
mined. Tobacco smoke contains many carcinogens, some of
which have been shown to affect gene promoter methylation
[12,31]. For instance, a study of rats treated with tobacco-
specific 4-methynitrosamino-1-(3-pyridy)-butanone (NNK)
showed that hypermethylated p16 gene promoter was de-
tected not only in lung adenocarcinomas but also in adeno-
mas and hyperplastic lesions, which represented precursor
lesions to the tumors, indicating a link between exposure to
NNK and p16 gene promoter aberrant methylation in lung
tumors and implicating this epigenetic alteration as an early
event in lung carcinogenesis [12].
It remains unclear how tobacco smoke carcinogens may
affect the methylation of theMGMT gene promoter. Grafstrom
et al. [32] showed that human epithelial cells treated with
acetaldehyde (another carcinogen present in tobacco smoke)
had a significantly decreased activity of the MGMT gene.
However, so far, there have been no reports linking acetalde-
hyde or other tobacco smoke carcinogens to aberrant meth-
ylation of the MGMT gene promoter.
The limitations of this study may be the small number of
lung tumors from never-smokers, due to the low incidence of
lung cancer among never-smoking individuals. Furthermore,
because the DNA samples analyzed were obtained from
surgically resected tumors, the incidence of promoter meth-
ylation observed may not indicate the incidence in the whole
non–small cell lung cancer population.
In conclusion, our study showed a higher frequency of
promoter methylation for the p16 and MGMT genes in lung
tumors from smokers compared with never-smokers, indicat-
ing an association between tobacco use and the increased in-
cidence of promotermethylation of these genes in lung cancer.
In spite of the relatively small number of never-smokers avail-
able for our study, the strength of our data was the homoge-
neity of the lung cancer patient population, all of whom were
white and from the Western Pennsylvania region. These re-
sultsmay be useful for the future study of smoking-related epi-
genetic changes in lung carcinogenesis. It will be of interest to
further investigate methylation differences between smokers
and never-smokers in other genes that have been found to
be frequently hypermethylated in lung tumors and in a larger
number of patients.
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